2Seventy Bio Inc (TSVT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, 2Seventy Bio Inc (TSVT) has a cash flow conversion efficiency ratio of -0.051x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.97 Million) by net assets ($213.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 2Seventy Bio Inc (TSVT) net asset quality to measure how much of total assets are equity-financed.
2Seventy Bio Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how 2Seventy Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 2Seventy Bio Inc cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
2Seventy Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 2Seventy Bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Libra Insurance Company Ltd
TA:LBRA
|
-0.075x |
|
Soulpower Acquisition Corporation
NYSE:SOUL
|
-0.006x |
|
Shanghai Chlor-Alkali Chemical Co Ltd B
SHG:900908
|
0.014x |
|
What's Cooking Group NV/SA
BR:WHATS
|
0.010x |
|
Pruksa Holding Public Company Limited
BK:PSH
|
0.024x |
|
Weifu High Tech Group
SHE:200581
|
0.049x |
|
Jilin Jlu Communication Design Institute Co Ltd
SHE:300597
|
-0.010x |
|
Tredegar Corporation
NYSE:TG
|
0.009x |
Annual Cash Flow Conversion Efficiency for 2Seventy Bio Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of 2Seventy Bio Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see 2Seventy Bio Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $210.81 Million | $-85.00 Million | -0.403x | +38.31% |
| 2023-12-31 | $255.30 Million | $-166.86 Million | -0.654x | +14.43% |
| 2022-12-31 | $310.47 Million | $-237.13 Million | -0.764x | -32.75% |
| 2021-12-31 | $359.82 Million | $-207.03 Million | -0.575x | +36.66% |
| 2020-12-31 | $74.63 Million | $-67.79 Million | -0.908x | +80.91% |
| 2019-12-31 | $43.69 Million | $-207.96 Million | -4.760x | -- |
About 2Seventy Bio Inc
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. 2seventy bio, Inc. was inco… Read more